NEJM publishes long-term results of Gleevec for 1,106 patients worldwide

NCCN updates CML treatment guidelines following FDA approval of Scemblix for newly diagnosed patients

The National Comprehensive Cancer Network updated its chronic myeloid leukemia treatment guidelines, recommending Scemblix (asciminib) for the treatment of adults with newly diagnosed Ph+ CML-CP as a category 1-preferred.

November 22, 2024

Vol.50 No.44

Drugs & Targets

FDA approves Scemblix for newly diagnosed CML patients

Scemblix (asciminib) was granted accelerated approval by FDA for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.

November 01, 2024

Vol.50 No.41

Drugs & Targets

FDA grants Priority Review to Scemblix for newly-diagnosed Ph+ CML-CP

FDA has granted Priority Review status to Scemblix (asciminib) for treatment of newly-diagnosed adult patients with Philadelphia chromosome-positive CML in chronic phase.

August 02, 2024

Vol.50 No.31

Clinical Roundup

Scemblix improves MMR rates for Ph+ CML-CP in phase III trial

Novartis presented positive results from the pivotal phase III ASC4FIRST trial as a late-breaking abstract at the 2024 American Society of Clinical Oncology meeting.

May 31, 2024

Vol.50 No.22

Drugs & Targets

FDA approves Bosulif for pediatric patients with CML

FDA has approved Bosulif (bosutinib) for pediatric patients ages one year and older with chronic phase (CP) Ph+ chronic myelogenous leukemia (CML) that is newly diagnosed or resistant or intolerant (R/I) to prior therapy.

September 29, 2023

Vol.49 No.36

Drugs & Targets

EU approval granted to Novartis SCEMBLIX for CML

The European Commission has approved Scemblix (asciminib) for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP), previously treated with two or more tyrosine kinase inhibitors.

September 09, 2022

Vol.48 No.32

NEJM publishes long-term results of Gleevec for 1,106 patients worldwide

YOU MAY BE INTERESTED IN

NCCN updates CML treatment guidelines following FDA approval of Scemblix for newly diagnosed patients

FDA approves Scemblix for newly diagnosed CML patients

FDA grants Priority Review to Scemblix for newly-diagnosed Ph+ CML-CP

Scemblix improves MMR rates for Ph+ CML-CP in phase III trial

FDA approves Bosulif for pediatric patients with CML

EU approval granted to Novartis SCEMBLIX for CML

Renew today!

Subscriber content

Never miss an issue!

Login